The lack of immunogenicity has practical implications: the peptide can be used for extended periods without loss of efficacy due to antibody neutralization, there is minimal risk of allergic or hypersensitivity reactions, and repeated treatment cycles are supported as prior exposure does not sensitize the immune system
TB-500 is typically administered via subcutaneous (under the skin) or intramuscular injection, usually 2-3 times per week
However, proBDNF, constituting only 10% of the total circulating concentration, does not correlate with platelet activation
The nasal route facilitates non-invasive administration, avoiding the need for injections or complex delivery systems, which may simplify protocol designs during experimental procedures
But the FDA has previously warned that they pose safety risks and barred pharmacies from compounding many of them
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)
